Cyllene Therapeutics

Cyllene Therapeutics is a clinical-stage biotechnology company pioneering next-generation precision genetic medicines for prevalent chronic neurological and neuro-urological diseases. Utilizing its proprietary non-replicating Herpes Simplex Virus 1 (nrHSV-1) vector platform, known as HERMES, the company designs therapies that achieve safe, targeted, and durable transgene expression in peripheral neurons. Cyllene's lead candidate, EG110A, is currently in Phase 1/2 clinical development for neurogenic detrusor overactivity (NDO) in patients with spinal cord injury, demonstrating significant reductions in urinary incontinence. The company is also expanding its pipeline to address other high-burden conditions, including overactive bladder, spasticity, pain, and migraine.